Memory Imaging of Normal Aging

This study has been completed.
Sponsor:
Information provided by:
National Institute on Aging (NIA)
ClinicalTrials.gov Identifier:
NCT00315575
First received: April 14, 2006
Last updated: January 22, 2009
Last verified: January 2009

April 14, 2006
January 22, 2009
August 2005
July 2008   (final data collection date for primary outcome measure)
identification of consistent patterns of variance in brain function in subjects at risk for Alzheimer's Disease by using APOE ε4 as a marker for disease risk [ Time Frame: single time point ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00315575 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Memory Imaging of Normal Aging
BOLD and Perfusion fMRI of Alzheimer's Disease Risk

The purpose of this study is to develop imaging techniques that can distinguish functional brain changes in people at high risk for dementia years prior to onset of clinical memory problems from those with normal changes of aging.

The overall goals of this project are to identify consistent patterns of variance in brain function in patients at risk for Alzheimer's Disease by using APOE ε4 as a marker for disease risk. The activation Blood Oxygen Level Dependency (BOLD) signal will be compared to both resting and activation perfusion signals to assess the variability of cerebral blood flow as it relates to the BOLD signal. Each participant will be imaged on a 3T MRI scanner while performing an associate episodic memory task.

A total of 90 individuals will be recruited for this study. Participants will be non-demented, right handed, adults with or without at least one APOE ε4 allele. Groups will be split as follows: A) ages 25-39: non-ε4 (n=15); B) ages 25-39: +ε4 (n=15); C) ages 40-49: non-ε4 (n=15); D) ages 40-49: +ε4 (n=15);.E) ages 50-65: non-ε4: F) ages 50-65: +ε4 (n=15). These groups will be matched for mean age, mean years of education, gender distribution, as well as the presence or absence of a family history of AD in a first degree relative.

There will be 2 scanning sessions for each participant. Scan session #1 and Scan session #2 will be acquired within 2 weeks of each other and will take approximately one hour each.

Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

healthy adults from the community

Alzheimer's Disease
Procedure: BOLD and Perfusion brain MRI
Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
  • 1
    Individuals with high risk for Alzheimer's disease
    Intervention: Procedure: BOLD and Perfusion brain MRI
  • 2
    Individuals with low risk for Alzheimer's disease
    Intervention: Procedure: BOLD and Perfusion brain MRI

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
90
July 2008
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Right-handed

Exclusion Criteria:

  • Major medical illnesses
  • History of significant head trauma with residual cognitive deficits
  • Other neurological or major psychiatric disorders such as schizophrenia, bipolar disorder, developmental learning disorder, and alcohol or substance abuse
  • MRI contra-indications
Both
25 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00315575
IA0092, 5K23AG024062-02
No
Adam Fleisher, MD, University of California, San Diego
National Institute on Aging (NIA)
Not Provided
Principal Investigator: Adam Fleisher, MD University of California, San Diego
National Institute on Aging (NIA)
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP